1. Basic introduction
Akeso Group is a clinical-stage biopharmaceutical company integrating capabilities in discovery, research, development, manufacturing, and business expansion. Akeso Group has developed a proprietary antibody discovery platform, the Immune Tolerance Breakthrough (IMTB) technology platform, enabling the generation of antibodies against non-conservative and conservative proteins that are difficult to generate in rodent animals, and the discovery of hidden epitopes that are difficult to find using traditional platforms. Through the IMTB technology platform, Akeso Group has developed TST001 (targeting Claudin 18.2 conservative epitope) and MSB2311 (a targeted antibody that binds to the epitope, making MSB2311 exhibit pH-dependent antigen binding properties of Programmed Death-Ligand 1 (PD-L1, a protein that controls immune responses)).
Number of shares offered: 40,330,000 shares (subject to the exercise of the over-allotment option).
The number of shares offered for public sale: 4,033,000 shares (10%, subject to reallocation)
The number of shares placed: 36,297,000 shares (90%, subject to reallocation and depending on the exercise of the over-allotment option)
Call back mechanism:
Insufficient shares in the public offering but sufficient shares in the international allocation: the shortfall will be called back to the international allocation
Insufficient shares in the international allocation: can be called back up to 20% and must have a lower limit price
International placement is fully subscribed and the public offering oversubscribed by less than 15 times: the clawback can be up to no more than 20% and needs to be ...